

**INTENDED USE**

The Filariasis IgG/IgM Rapid Test is a lateral flow immunoassay for the simultaneous detection and differentiation of IgG and IgM antibodies to lymphatic filarial parasites (*W. Bancrofti* and *B. Malayi*) in human serum, plasma or whole blood. It is intended to be used by professionals as a screening test and provides a preliminary test result to aid in the diagnosis of infection with lymphatic filarial parasites.

Any use or interpretation of this preliminary test result must also rely on other clinical findings and the professional judgement of the health care providers. Alternative test method(s) should be considered to confirm the test result obtained by this device.

**SUMMARY AND EXPLANATION OF THE TEST**


Lymphatic filariasis, commonly known as Elephantiasis, is mainly caused by *W. bancrofti* and *B. malayi* and affects about 120 million people across 80 countries<sup>1,2</sup>. The disease is transmitted to humans by the bites of infected mosquitoes within which the microfilariae sucked from an infected human subject develops into third-stage larvae. Generally, repeated and prolonged exposure to infected larvae is required for establishment of human infection.

The definitive parasitologic diagnosis is the demonstration of microfilariae in blood samples<sup>3</sup>. However, this gold standard test is restricted by the requirement for nocturnal blood collection and lack of adequate sensitivity. Detection of circulating antigens is another commercially available diagnostic method, but its usefulness is limited to infection with *W. bancrofti*<sup>4</sup>. In addition, microfilaremia and antigenemia develop from months to years after exposure.

Antibody detection provides an early means to detect filarial parasite infection. Presence of IgM to the parasite antigens suggests current infection, whereas, presence of IgG corresponds to late stage of infection or past infection<sup>5</sup>. Furthermore, identification of conserved antigens allows 'pan-filaria' tests to be applicable. Utilization of recombinant proteins eliminates cross-reaction with individuals having other parasitic diseases<sup>6</sup>. The Filariasis IgG/IgM Rapid Test uses conserved recombinant antigens to simultaneously detect IgG and IgM to the *W. bancrofti* and *B. malayi* parasites without the restriction on specimen collection.

**TEST PRINCIPLE**

The Filariasis IgG/IgM Rapid Test is a lateral flow chromatographic immunoassay. The test cassette consists of: 1) a burgundy colored conjugate pad containing recombinant *W. bancrofti* and *B. malayi* common antigens conjugated with colloidal gold (Filariasis conjugates) and a control antibody conjugated with colloidal gold, 2) a nitrocellulose membrane strip containing two test lines (M and G lines) and a control line (C line). The M line is pre-coated with monoclonal anti-human IgM for the detection of IgM to *W. bancrofti* and *B. malayi*, the G line is pre-coated with reagents for the detection of IgG to *W. bancrofti* and *B. malayi*, and the C line is pre-coated with a control antibody.



When an adequate volume of test specimen is dispensed into the sample well of the cassette, the specimen migrates by capillary action across the cassette. Anti-*W. bancrofti* or anti-*B. malayi* IgM antibodies if present in the specimen will bind to the Filariasis conjugates. The immunocomplex is then captured on the membrane by the pre-coated anti-human IgM antibody forming a burgundy colored M line, indicating a anti-*W. bancrofti* or anti-*B. malayi* IgM positive test result.

Anti-*W. bancrofti* or anti-*B. malayi* IgG antibodies if present in the specimen will bind to the Filariasis conjugates. The immunocomplex is then captured by the pre-coated reagents on the membrane forming a burgundy colored G line, indicating an anti-*W. bancrofti* or anti-*B. malayi* IgG positive test result.

Absence of any test lines (M and G) suggests a negative result. The test contains an internal control (C line) which should exhibit a burgundy colored line of the immunocomplex of the control antibodies regardless of the color development on any of the test lines. If the C line does not develop, the test result is invalid and the specimen must be retested with another device.

**REAGENTS AND MATERIALS PROVIDED**

- Individually sealed foil pouches containing:
  - One cassette device
  - One desiccant
- Plastic droppers
- Sample diluent (5 mL/bottle)
- One package insert (instruction for use)

**MATERIALS REQUIRED BUT NOT PROVIDED**

- Clock or timer.
- Disposable gloves
- Lancing device for whole blood test

**WARNINGS AND PRECAUTIONS**

**For in Vitro Diagnostic use**

- This package insert must be read completely before performing the test. Failure to follow the insert gives inaccurate test results.
- Do not open the sealed pouch unless ready to conduct the assay.
- Do not use expired devices.
- Bring all reagents to room temperature (15-30°C) before use.
- Do not use the components in any other type of test kit as a substitute for the components in this kit.
- Do not use hemolyzed blood specimen for testing.
- Wear protective clothing and disposable gloves while handling the kit reagents and clinical specimens. Wash hands thoroughly after performing the test.

- Users of this test should follow the US CDC Universal Precautions for prevention of transmission of HIV, HBV and other blood-borne pathogens.
- Do not smoke, drink or eat in areas where specimens or kit reagents are being handled.
- Dispose of all specimens and materials used to perform the test as bio-hazardous waste.
- Handle the negative and positive controls in the same manner as patient specimens.
- The test results should be read 15 minutes after a specimen is applied to the sample well of the device. Any results interpreted outside of the 15 minute window should be considered invalid and must be repeated.
- Do not perform the test in a room with strong air flow, i.e. an electric fan or strong air-conditioning.

**REAGENT PREPARATION AND STORAGE INSTRUCTIONS**

All reagents are ready to use as supplied. Store unused test device unopened at 1-30°C. If stored at 2-8°C, ensure that the test device is brought to room temperature before opening. The test device is stable through the expiration date printed on the sealed pouch. Do not freeze the kit or expose the kit to temperatures above 30°C.

**SPECIMEN COLLECTION AND HANDLING**

Consider any materials of human origin as infectious and handle them using standard bio- safety procedures.

**Plasma/Serum**

- Step 1: Collect blood specimen into collection tube containing EDTA, citrate or heparin for plasma or collection tube containing no anticoagulants for serum by venipuncture.
- Step 2: To make plasma specimen, centrifuge collected specimens and carefully withdraw the plasma into a new pre-labeled tube.
- Step 3: To make serum specimen, allow blood to clot, then centrifuge collected specimens and carefully withdraw the serum into a new pre-labeled tube.

Test specimens as soon as possible after collecting. Store specimens at 2-8°C, if not tested immediately. The specimens can be stored at 2-8°C for up to 5 days. The specimens should be frozen at -20°C for longer storage.

Avoid multiple freeze-thaw cycles. Prior to testing, bring frozen specimens to room temperature slowly and mix gently. Specimens containing visible particulate matter should be clarified by centrifugation before testing.

Do not use samples demonstrating gross lipemia, gross hemolysis or turbidity in order to avoid interference with result interpretation.

**Whole Blood**

- Step 1: Drops of whole blood can be obtained by either fingertip puncture or venipuncture. Collect blood specimen into a collection tube containing EDTA, citrate or heparin. Do not use hemolyzed blood for testing.



Whole blood specimens should be stored in refrigeration (2-8°C), if not tested immediately. The specimens must be tested within 24 hours of collection.

**ASSAY PROCEDURE**

- Step 1: Bring the specimen and test components to room temperature if refrigerated or frozen. Mix the specimen well, prior to assay, once thawed.
- Step 2: When ready to test, open the pouch at the notch and remove the device. Place the test device on a clean, flat surface.
- Step 3: Be sure to label the device with the specimen's ID number.
- Step 4: Fill the plastic dropper with the specimen.

Holding the dropper vertically, dispense 1 drop (about 30-45 µL) of serum/plasma or 1 drop of whole blood (about 40-50 µL) into the sample well making sure that there are no air bubbles.

Immediately add 1 drop (about 35-50 µL) of sample diluent to the sample well with the bottle positioned vertically.



- Step 5: Set up timer.
- Step 6: Results can be read at 15 minutes. Positive results can be visible in as soon as 1 minute. Negative results must be confirmed at the end of the 15 minutes only. **Any results interpreted outside of the 15 minute window should be considered invalid and must be repeated. Discard used devices after interpreting the result following local requirements governing the disposal of devices.**

**QUALITY CONTROL**

- Internal Control:** This test contains a built-in control feature, the C line. The C line develops after adding specimen and the sample diluent. If the C line does not develop, review the whole procedure and repeat the test with a new device.
- External Control:** Good Laboratory Practice recommends using external controls, positive and negative, to assure the proper performance of the assay, particularly under the following circumstances:
  - A new operator uses the kit, prior to performing the testing of specimens.
  - A new lot of test kits is used.
  - A new shipment of test kits is used.
  - The temperature used during storage of the kits fall outside of 1-30 °C.
  - The temperature of the test area falls outside of 15-30 °C.
  - To verify a higher than expected frequency of positive or negative results.
  - To investigate the cause of repeated invalid results.

**INTERPRETATION OF ASSAY RESULT**

- NEGATIVE RESULT:** If only the C line is present, the absence of any burgundy color in both test lines (M and G) indicates that no anti-*W. bancrofti* or *B. malayi* IgG or IgM antibody is detected in the specimen. The result is non-reactive or negative.



**2. POSITIVE RESULT:**

- In addition to the presence of the C line, if only the M line develops, the test indicates the presence of anti-*W. bancrofti* or anti-*B. malayi* IgM antibody. The result is IgM reactive or positive.



- In addition to the presence of the C line, if only the G line develops, the test indicates the presence of anti-*W. bancrofti* or anti-*B. malayi* IgG antibody. The result is IgG reactive or positive.




- In addition to the presence of the C line, if both the M and the G lines develop, the test indicates the presence of both anti-*W. bancrofti* or anti-*B. malayi* IgG and IgM. The result is both IgG and IgM reactive or positive.



Samples with reactive results should be confirmed with alternative testing method(s) and clinical findings before a diagnosis decision is made.

- INVALID:** If no C line develops, the assay is invalid regardless of any burgundy color in the test lines as indicated below. Repeat the assay with a new device.



**PERFORMANCE CHARACTERISTICS**

**1. Clinical Performance for IgM Test**

24 samples from patient with acute lymphatic filariasis and 400 samples collected from a non-filariasis region were tested by the TRUSTline Filariasis IgG/IgM Rapid Test. Comparison for all subjects is shown in the following table.

TRUSTline Filariasis IgG/IgM Rapid Test			
Clinical Status	Positive	Negative	Total
Acute filariasis	23	1	24
Negative	1	399	400
Total	24	400	424

Relative Sensitivity: 95.83%, Relative Specificity: 99.75%, Overall Agreement: 99.53%

**2. Clinical Performance for IgG Test**

66 samples from patient with chronic lymphatic filariasis and 400 samples collected from a non-filariasis region were tested by the TRUSTline Filariasis IgG/IgM Rapid Test. Comparison for all subjects is shown in the following table.

TRUSTline Filariasis IgG/IgM Rapid Test			
Clinical Status	Positive	Negative	Total
Chronic filariasis	63	3	66
Negative	1	399	400
Total	64	402	466

Relative Sensitivity: 95.45%, Relative Specificity: 99.75%, Overall Agreement: 99.14%

**LIMITATIONS OF TEST**

- The Assay Procedure and the Interpretation of Assay Result sections must be followed closely when testing for the presence of IgG and IgM antibodies to filarial parasites in serum, plasma or whole blood from individual subjects. Failure to follow the procedure may give inaccurate results.
- The Filariasis IgG/IgM Rapid Test is limited to the qualitative detection of IgG and IgM antibodies to *W. bancrofti* and *B. malayi* in human serum, plasma or whole blood. The intensity of the test line does not have a linear correlation with the antibody titer in the specimen.
- A nonreactive result for an individual subject indicates absence of detectable anti-*W. bancrofti* and anti-*B. malayi* IgG and IgM antibodies. However, a nonreactive test result does not preclude the possibility of exposure to *W. bancrofti* and *B. malayi*.
- A nonreactive result can occur if the quantity of *W. bancrofti* and *B. malayi* antibodies present in the specimen is below the detection limits of the assay or the antibodies that are detected are not present during the stage of disease in which a sample is collected.
- If the symptoms persist while the result from Filariasis IgG/IgM Rapid Test is nonreactive, it is recommended to test with an alternative test method such as ELISA.
- Some specimens containing unusually high titers of heterophile antibodies or rheumatoid factor may affect expected results.
- The results obtained with this test should only be interpreted in conjunction with other diagnostic procedures and clinical findings.

**REFERENCES**

- Lymphatic filariasis: the disease and its control. Fifth report of the WHO Expert Committee on Filariasis. WHO Tech Rep Ser 1992; 281-871.
- Michael E, Bundy DAP, Grenfell BT. Re-assessing the global prevalence and distribution of lymphatic filariasis. Parasitology 1996; 112:405-428.
- Eberhard ML, Lammie PJ. Laboratory diagnosis of filariasis. Clin. Lab Med 1991; 11:977-1010.
- More SJ, Copeman DB. A highly specific and sensitive monoclonal antibody-based ELISA for the detection of circulating antigen in bancroftian filariasis. Trop Med Parasitol 1990; 41:403-406.
- Lammie PJ, Weil G, et al: Recombinant antigen-based antibody assays for the diagnosis surveillance of lymphatic filariasis-a multiplex trial. Flaria Jornal 2004; 3: 9-18.
- Baskar LK, Srikanth TR, et al: Development and evaluation of a rapid flow-through immunofiltration test using recombinant filarial antigen for diagnosis of brugian and bancroftian filariasis. Microbiol Immunol. 2004; 48: 519-25.

**Index of Symbols**

	Consult instructions for use		Catalogue number		Use-by date
	For <i>in vitro</i> diagnostic use only		Batch code		Tests per kit
	Temperature limit 1-30 °C		Do not re-use		Keep dry
	Manufacturer		Date of manufacture		Warnings / Precautions
	If device is non-sterile		Keep away from sunlight		
	Do not use if package is damaged				

**AtheneDx Pvt. Ltd.**  
 Module No. 407 & 408, 4<sup>th</sup> Floor,  
 TICEL Bio Park II, No. 5, CSIR Road,  
 Taramani, Chennai-600113, India  
 Tel: +91-44-22541131  
 E-mail: info@athenesedx.com  
 Website: www.athenesedx.com

PI-AR0151C Rev. C  
 Effective date: 01.08.2022  
 English version